This is a tremendous area to be involved in because it has all the upside that comes with high-growth biotechnology research … but much less risk as Iqvia itself isn't trying to develop new and unproven drugs for rare diseases. It's also fairly low risk in the current environment as the pharmaceuticals industry continues to invest heavily in R&D. As a result, IQV stock is predicting 5% revenue growth and 13% earnings growth this year that accelerates to 10% sales growth and 15% profit growth in fiscal 2023.